Evoke Pharma, Inc., a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that the United States Patent and Trademark Office (USPTO) issued US patent No. 11,628,150 under the title “Nasal Formulations of Metoclopramide.”

This patent expires in 2029 and covers the nasal solution of metoclopramide and its characteristics when formulated. The patent augments Evoke’s existing patent portfolio, which includes U.S. Food and Drug Administration (FDA) Orange Book-listed patents and other patents in the EU, Japan, Canada, and Mexico. The Company will seek to list this patent in the FDA Orange-Book in the near term.

“We view this patent approval and the others we’ve received to date from the USPTO as evidence of the innovation behind our product, GIMOTI and its significant contribution to the GI community, particularly patients,” commented Matt D’Onofrio, President & COO. “This patent will continue to protect GIMOTI’s proprietary route of administration which is incredibly important to our commercial efforts,” Mr. D’Onofrio concluded.

Source: globenewswire.com